FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978271300> ?p ?o ?g. }

• W2978271300 endingPage "v123" @default.
• W2978271300 startingPage "v123" @default.
• W2978271300 abstract "Abstract Background The androgen receptor (AR) is expressed in ∼ 90% of ER+ BC. Androgen-based therapies have had response rates up to 20-25%, but are not in common use due to poor tissue selectivity, potential aromatization to estrogen, and emergence of ER-targeted agents. RAD140 is an oral nonsteroidal selective AR modulator (SARM) with tissue-selective AR agonist activity in BC cells but attenuated activity in other androgen-responsive tissues. RAD140 inhibited the growth of multiple in vitro and in vivo AR+/ER+ BC models. Methods This is a phase 1 study of RAD140 with a 3 + 3 design. The primary objective is safety and to determine the maximum tolerated dose (MTD); secondary objectives are pharmacokinetics and antitumor activity. Key eligibility criteria are: ER+/HER2- and inoperable/metastatic BC (mBC), post-menopausal, and ineligible for standard therapy. AR status is by immunohistochemistry (IHC). Sex hormone-binding globulin (SHBG) and serum prostate specific antigen (PSA) are used to assess AR-engagement. Results Dose escalation (n = 16 patients, pts) has been completed. Median age = 58 years, 88% visceral disease, and 94% AR+ by IHC. Median number of prior lines of therapy for mBC = 5; prior fulvestrant 88%, aromatase inhibitor (i) 100%, CDK4/6i 94%, mTORi/PI3Ki 50%, chemotherapy 94%. Dose levels were 50 mg (n = 6), 100 mg (n = 7), and 150 mg (n = 3) QD. Median time on treatment = 8 (range 30%) adverse events were elevated ALT/AST, decreased weight/appetite, and constipation. Dose-limiting toxicities (all grade 3 and reversible) were hypophosphatemia (n = 2; 150 mg) and elevated ALT/AST (n = 2; 50 and 100 mg). No drug-related deaths occurred. There was 1 partial response (PR, 100 mg) and 2 pts with stable disease ≥12 wk. The time to PR was 15.9 wk and the duration was 8.6+ wk. SHBG decreased in 12/12 pts and PSA increased in 10/14 pts, most notably in the pt with PR who remains on treatment at 7 mo. Conclusions The provisional MTD for RAD140 is 100 mg QD. RAD140 is a novel oral AR-targeted agent for treatment of ER+ mBC with an acceptable safety profile and preliminary evidence of target engagement and antitumor activity. NCT03088527. Clinical trial identification NCT03088527. Legal entity responsible for the study Radius Health, Inc. Funding Radius Health, Inc. Disclosure E. Hamilton: Advisory / Consultancy: Flatiron Health; Travel / Accommodation / Expenses: Amgen; Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Clovis Oncology; Research grant / Funding (institution), Travel / Accommodation / Expenses: Eisai; Travel / Accommodation / Expenses: EMD Serono; Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Travel / Accommodation / Expenses: Genzyme; Travel / Accommodation / Expenses: Helsinn Therapeutics; Travel / Accommodation / Expenses: HERON; Travel / Accommodation / Expenses: Lexicon; Research grant / Funding (institution), Travel / Accommodation / Expenses: Medivation; Travel / Accommodation / Expenses: Merck; Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Sysmex; Research grant / Funding (institution), Travel / Accommodation / Expenses: Tesaro. N. Vidula: Research grant / Funding (institution): Radius Health; Research grant / Funding (institution): Daewha; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Pfizer. C. Ma: Research grant / Funding (self): Eisai; Research grant / Funding (self): Puma; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy: Lilly; Advisory / Consultancy: Syndex; Advisory / Consultancy: Seattle Genetics. R.G. Bagley: Shareholder / Stockholder / Stock options, Full / Part-time employment: Radius Health. Z. Yu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Radius Health. M. Annett: Shareholder / Stockholder / Stock options, Full / Part-time employment: Radius Health. A. Weitzman: Shareholder / Stockholder / Stock options, Full / Part-time employment: Radius Health. M.G. Conlan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Radius Health. A. Weise: Speaker Bureau / Expert testimony: Array BioPharma. All other authors have declared no conflicts of interest." @default.
• W2978271300 created "2019-10-10" @default.
• W2978271300 creator A5001906020 @default.
• W2978271300 creator A5003060935 @default.
• W2978271300 creator A5017967471 @default.
• W2978271300 creator A5024546399 @default.
• W2978271300 creator A5035849162 @default.
• W2978271300 creator A5038563211 @default.
• W2978271300 creator A5039802529 @default.
• W2978271300 creator A5058408204 @default.
• W2978271300 creator A5072913342 @default.
• W2978271300 creator A5085041670 @default.
• W2978271300 date "2019-10-01" @default.
• W2978271300 modified "2023-10-16" @default.
• W2978271300 title "Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC)" @default.
• W2978271300 doi "https://doi.org/10.1093/annonc/mdz242.038" @default.
• W2978271300 hasPublicationYear "2019" @default.
• W2978271300 type Work @default.
• W2978271300 sameAs 2978271300 @default.
• W2978271300 citedByCount "3" @default.
• W2978271300 countsByYear W29782713002020 @default.
• W2978271300 countsByYear W29782713002021 @default.
• W2978271300 countsByYear W29782713002022 @default.
• W2978271300 crossrefType "journal-article" @default.
• W2978271300 hasAuthorship W2978271300A5001906020 @default.
• W2978271300 hasAuthorship W2978271300A5003060935 @default.
• W2978271300 hasAuthorship W2978271300A5017967471 @default.
• W2978271300 hasAuthorship W2978271300A5024546399 @default.
• W2978271300 hasAuthorship W2978271300A5035849162 @default.
• W2978271300 hasAuthorship W2978271300A5038563211 @default.
• W2978271300 hasAuthorship W2978271300A5039802529 @default.
• W2978271300 hasAuthorship W2978271300A5058408204 @default.
• W2978271300 hasAuthorship W2978271300A5072913342 @default.
• W2978271300 hasAuthorship W2978271300A5085041670 @default.
• W2978271300 hasBestOaLocation W29782713001 @default.
• W2978271300 hasConcept C121608353 @default.
• W2978271300 hasConcept C126322002 @default.
• W2978271300 hasConcept C143998085 @default.
• W2978271300 hasConcept C2777944059 @default.
• W2978271300 hasConcept C2780192828 @default.
• W2978271300 hasConcept C530470458 @default.
• W2978271300 hasConcept C61367390 @default.
• W2978271300 hasConcept C71924100 @default.
• W2978271300 hasConcept C84606932 @default.
• W2978271300 hasConceptScore W2978271300C121608353 @default.
• W2978271300 hasConceptScore W2978271300C126322002 @default.
• W2978271300 hasConceptScore W2978271300C143998085 @default.
• W2978271300 hasConceptScore W2978271300C2777944059 @default.
• W2978271300 hasConceptScore W2978271300C2780192828 @default.
• W2978271300 hasConceptScore W2978271300C530470458 @default.
• W2978271300 hasConceptScore W2978271300C61367390 @default.
• W2978271300 hasConceptScore W2978271300C71924100 @default.
• W2978271300 hasConceptScore W2978271300C84606932 @default.
• W2978271300 hasLocation W29782713001 @default.
• W2978271300 hasOpenAccess W2978271300 @default.
• W2978271300 hasPrimaryLocation W29782713001 @default.
• W2978271300 hasRelatedWork W192798436 @default.
• W2978271300 hasRelatedWork W2224319365 @default.
• W2978271300 hasRelatedWork W2348152691 @default.
• W2978271300 hasRelatedWork W2369039771 @default.
• W2978271300 hasRelatedWork W2953241133 @default.
• W2978271300 hasRelatedWork W3094957539 @default.
• W2978271300 hasRelatedWork W317834158 @default.
• W2978271300 hasRelatedWork W4281606715 @default.
• W2978271300 hasRelatedWork W4298002935 @default.
• W2978271300 hasRelatedWork W2555822460 @default.
• W2978271300 hasVolume "30" @default.
• W2978271300 isParatext "false" @default.
• W2978271300 isRetracted "false" @default.
• W2978271300 magId "2978271300" @default.
• W2978271300 workType "article" @default.